Cited 1 times in
Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강은석 | - |
dc.contributor.author | 김영은 | - |
dc.contributor.author | 배재현 | - |
dc.contributor.author | 이민영 | - |
dc.contributor.author | 이병완 | - |
dc.contributor.author | 이용호 | - |
dc.contributor.author | 차봉수 | - |
dc.date.accessioned | 2022-07-08T02:59:32Z | - |
dc.date.available | 2022-07-08T02:59:32Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/188610 | - |
dc.description.abstract | Purpose: To date, no study has compared the effects of adding sodium glucose cotransporter-2 (SGLT-2) inhibitors to the combination of metformin plus dipeptidyl peptidase-4 (DPP-4) inhibitors to the effects of adding other conventional anti-diabetic drugs (ADDs) to the dual therapy. We aimed to compare the effect of adding SGLT-2 inhibitors with that of adding sulfonylurea (SU) in type 2 diabetes (T2D) patients inadequately controlled with metformin plus DPP-4 inhibitors. Materials and methods: This study was designed to evaluate the non-inferiority of SGLT-2 inhibitor to SU as an add-on therapy to the dual combination of metformin plus DPP-4 inhibitors. A total of 292 T2D patients who started SU or SGLT-2 inhibitors as an add-on therapy to metformin plus DPP-4 inhibitors due to uncontrolled hyperglycemia, defined as glycated hemoglobin (HbA1c) ≥7%, were recruited. After propensity score matching, 90 pairs of patients remained, and 12-week changes in HbA1c levels were reviewed to assess glycemic effectiveness. Data from these patients were analyzed retrospectively. Results: After 12 weeks of triple therapy, both groups showed significant changes in HbA1c levels, with a mean of -0.9% in each group. The inter-group difference was 0.01% [95% confidence interval (CI): -0.26-0.27], and the upper limit of the 95% CI was within the limit for non-inferiority (0.40%). There were no inter-group differences in the changes of liver enzyme levels and kidney function. Conclusion: Adding SGLT-2 inhibitors is not inferior to adding SU as a third-line ADD to metformin plus DPP-4 inhibitor combination therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Diabetes Mellitus, Type 2* / drug therapy | - |
dc.subject.MESH | Dipeptidyl-Peptidase IV Inhibitors* / therapeutic use | - |
dc.subject.MESH | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / therapeutic use | - |
dc.subject.MESH | Glycated Hemoglobin A / analysis | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hypoglycemic Agents / therapeutic use | - |
dc.subject.MESH | Metformin* / therapeutic use | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use | - |
dc.title | Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jaehyun Bae | - |
dc.contributor.googleauthor | Young-Eun Kim | - |
dc.contributor.googleauthor | Minyoung Lee | - |
dc.contributor.googleauthor | Yong-Ho Lee | - |
dc.contributor.googleauthor | Byung-Wan Lee | - |
dc.contributor.googleauthor | Bong-Soo Cha | - |
dc.contributor.googleauthor | Eun Seok Kang | - |
dc.identifier.doi | 10.3349/ymj.2022.63.6.539 | - |
dc.contributor.localId | A00068 | - |
dc.contributor.localId | A06227 | - |
dc.contributor.localId | A01803 | - |
dc.contributor.localId | A05491 | - |
dc.contributor.localId | A02796 | - |
dc.contributor.localId | A02989 | - |
dc.contributor.localId | A03996 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 35619577 | - |
dc.subject.keyword | Type 2 diabetes mellitus | - |
dc.subject.keyword | glycemic control | - |
dc.subject.keyword | sodium-glucose cotransporter 2 inhibitors. | - |
dc.contributor.alternativeName | Kang, Eun Seok | - |
dc.contributor.affiliatedAuthor | 강은석 | - |
dc.contributor.affiliatedAuthor | 김영은 | - |
dc.contributor.affiliatedAuthor | 배재현 | - |
dc.contributor.affiliatedAuthor | 이민영 | - |
dc.contributor.affiliatedAuthor | 이병완 | - |
dc.contributor.affiliatedAuthor | 이용호 | - |
dc.contributor.affiliatedAuthor | 차봉수 | - |
dc.citation.volume | 63 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 539 | - |
dc.citation.endPage | 544 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.63(6) : 539-544, 2022-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.